A
AlcaSynn Pharmaceuticals
Drug development company focusing on small molecules of the morphinan group. In 2006 AlcaSynn was acquired by Sanochemia Pharmazeutika
About AlcaSynn Pharmaceuticals
AlcaSynn Pharmaceuticals GmbH, established in Innsbruck, Austria, operates as a drug development company with a focus on morphinan-based therapeutics. Founded in 2002 by Professor Dr. Helmut Schmidhammer and Dr. Johannes Schütz, the firm specializes in the preclinical and clinical development of highly potent opioid and non-opioid drugs. The company's core competency lies in the medicinal chemistry of morphinans, possessing a diverse portfolio of drug candidates aimed at various medical indications.
In June 2006, Sanochemia Pharmazeutika AG acquired a 60% majority stake in AlcaSynn, a transaction valued at 12 million euros. This strategic partnership provided Sanochemia with access to AlcaSynn's extensive technological base and development resources in pain management and central nervous system (CNS) disorders. AlcaSynn collaborates with other pharmaceutical companies to develop drugs based on synthetic morphinan derivatives. These compounds are designed for the treatment of conditions such as pain, inflammation, Parkinson's, and Alzheimer's disease. The business model centers on research and development, aiming to create novel opioid analgesics with improved efficacy and reduced side effects compared to traditional options like morphine.
The company's product development pipeline is built upon targeted molecular modifications of the morphinan scaffold. This approach aims to create multifunctional ligands that can target multiple opioid receptors, offering a potential alternative to analgesics that selectively target the mu-opioid receptor. By focusing on specific chemical modifications, AlcaSynn works to discover opioid analgesics with more favorable pharmacological properties. At the time of the acquisition by Sanochemia, AlcaSynn held a patent portfolio consisting of 13 awarded patents with an additional 26 pending.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Aug 2006 | $13M | $53M | Undisclosed | — |
Growth signals
Latest recorded traffic for AlcaSynn Pharmaceuticals is 1.5K monthly website visits, up 120.6% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
AlcaSynn Pharmaceuticals in the Innsbruck ecosystem
The AlcaSynn Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about AlcaSynn Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See AlcaSynn Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









